期刊文献+

Individualized treatment of gastric cancer:Impact of molecular biology and pathohistological features 被引量:5

Individualized treatment of gastric cancer:Impact of molecular biology and pathohistological features
下载PDF
导出
摘要 Gastric cancer is one of the most common malignancies worldwide.The overall prognosis remains poor over the last decades even though improvements in surgical outcomes have been achieved.A better understanding of the molecular biology of gastric cancer and detection of eligible molecular targets might be of central interest to further improve clinical outcome.With this intention,first steps have been made in the research of growth factor signaling.Regarding morphogens,cell cycle and nuclear factor-κB signaling,a remarkable count of target-specific agents have been developed,nevertheless the transfer into the field of clinical routine is still at the beginning.The potential utility of epigenetic targets and the further evaluation of micro RNA signaling seem to have potential for the development of novel treatment strategies in the future. Gastric cancer is one of the most common malignancies worldwide.The overall prognosis remains poor over the last decades even though improvements in surgical outcomes have been achieved.A better understanding of the molecular biology of gastric cancer and detection of eligible molecular targets might be of central interest to further improve clinical outcome.With this intention,first steps have been made in the research of growth factor signaling.Regarding morphogens,cell cycle and nuclear factor-κB signaling,a remarkable count of target-specific agents have been developed,nevertheless the transfer into the field of clinical routine is still at the beginning.The potential utility of epigenetic targets and the further evaluation of micro RNA signaling seem to have potential for the development of novel treatment strategies in the future.
机构地区 Department of General
出处 《World Journal of Gastrointestinal Oncology》 SCIE CAS 2015年第11期292-302,共11页 世界胃肠肿瘤学杂志(英文版)(电子版)
关键词 GASTRIC cancer Molecular BIOLOGY TARGETED THERAPY Gastric cancer Molecular biology Targeted therapy
  • 相关文献

参考文献20

  • 1Shaheenah Dawood,Bhawna Sirohi.Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer[J]. Future Oncol. . 2015 (6)
  • 2Lin Shen,Jin Li,Jianming Xu,Hongming Pan,Guanghai Dai,Shukui Qin,Liwei Wang,Jinwan Wang,Zhenzhou Yang,Yongqian Shu,Ruihua Xu,Lei Chen,Yunpeng Liu,Shiying Yu,Lilian Bu,Yongzhe Piao.Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)[J]. Gastric Cancer . 2015 (1)
  • 3Hansjochen Wilke,Kei Muro,Eric Van Cutsem,Sang-Cheul Oh,Gy?rgy Bodoky,Yasuhiro Shimada,Shuichi Hironaka,Naotoshi Sugimoto,Oleg Lipatov,Tae-You Kim,David Cunningham,Philippe Rougier,Yoshito Komatsu,Jaffer Ajani,Michael Emig,Roberto Carlesi,David Ferry,Kumari Chandrawansa,Jonathan D Schwartz,Atsushi Ohtsu.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncology . 2014 (11)
  • 4Timothy Iveson,Ross C Donehower,Irina Davidenko,Sergey Tjulandin,Andrzej Deptala,Mark Harrison,Somanath Nirni,Kuntegowdanahalli Lakshmaiah,Anne Thomas,Yizhou Jiang,Min Zhu,Rui Tang,Abraham Anderson,Sarita Dubey,Kelly S Oliner,Elwyn Loh.Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study[J]. Lancet Oncology . 2014 (9)
  • 5Masaru Katoh,Hitoshi Nakagama.FGF Receptors: Cancer Biology and Therapeutics[J]. Med. Res. Rev. . 2014 (2)
  • 6Fuyi Tong,Peng Cao,Yuan Yin,Suhua Xia,Rensheng Lai,Shenlin Liu.MicroRNAs in Gastric Cancer: From Benchtop to Bedside[J]. Digestive Diseases and Sciences . 2014 (1)
  • 7Giuseppe Aprile,Marta Bonotto,Elena Ongaro,Carmelo Pozzo,Francesco Giuliani.Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use[J]. Drugs . 2013 (18)
  • 8Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer[J]. Cancer Letters . 2011 (2)
  • 9HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing[J]. Virchows Archiv . 2010 (3)
  • 10James A Bonner,Paul M Harari,Jordi Giralt,Roger B Cohen,Christopher U Jones,Ranjan K Sur,David Raben,Jose Baselga,Sharon A Spencer,Junming Zhu,Hagop Youssoufian,Eric K Rowinsky,K Kian Ang.Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival[J]. Lancet Oncology . 2010 (1)

共引文献15

同被引文献28

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部